SINGAPORE, Dec. 29, 2022 (GLOBE NEWSWIRE) — ALR Technologies SG Ltd. (“ALRT”) (OTCQB:ALRTF), the diabetes management company, today announced the completion of a long-term manufacturing and supply agreement with Infinovo Medical Co. Ltd (“Infinovo”) for the Continuous Glucose Monitor (CGM) hardware used in the GluCurve Pet CGM. The agreement gives ALRT the exclusive global rights to distribute the CGM hardware in the animal health market.
Additionally, the Company announces it anticipates December and fourth quarter of 2022 sales to be in the range of $145,000 and $155,000. The Company expects Q1 2023 sales to be in the range of $450,000 to $600,000 with the possibility of an adjustment upwards subject to increased production capacity.
“December reflects a turning point for ALRT as we look to close out the fiscal year with our first quarter of meaningful sales, along with an attractive gross profit,” said Sidney Chan, Chairman and CEO of ALRT. “We will be exhibiting the GluCurve Pet CGM at CES January 5th-8th and VMX (Veterinary Meeting and Expo) January 14th-18th which should bolster awareness around the Company and GluCurve. The number of available units will increase quarter over quarter throughout 2023 resulting in a significant rise in sales as it will enable our distribution partner, Covetrus, to launch GluCurve throughout the US, EU, and other key markets.”
About Infinovo Medical Co. Ltd:
Founded in 2016, Infinovo is an innovative medical technology company, focusing on developing an accurate and affordable CGM for patients which will be available for both Type 1 and Type 2 Diabetics. https://infinovo.com
About ALR Technologies SG Ltd.
ALRT is a data management company that developed the ALRT Diabetes Solution, a comprehensive approach to diabetes care that includes an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters and continuous glucose monitoring devices, and a patent pending Predictive A1C algorithm to track treatment success between lab reports and an FDA-cleared Insulin Dosing Adjustment program. The overall goal is to optimize diabetes drug therapies to drive improved patient outcomes.
In addition, the animal health division of ALRT has developed the GluCurve Pet CGM; a solution to assist veterinarians better determine the efficacy of insulin treatments and to help to identify the appropriate dose and frequency of administration for companion animals, thereby delivering the same optimization of diabetic drug therapies to pets as to humans.
More information about ALRT can be found at www.alrt.com and https://sg.alrt.com.
Investor Contact
Investor Relations: ir@alrt.com
Animal Health Inquiries: animalhealth@alrt.com
Media: Media@alrt.com
US: +1 804 554 3500
Singapore: +65 3129 2924
ALR Technologies SG Ltd. Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding future sales and revenues, expected levels of product inventory and demand, strategy for customer retention, growth, product distribution, market penetration and expansion, financial results and reserves, and strategy for risk management. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: failure to generate anticipated company and product awareness, inability to maintain production capacity sufficient to meet customer demand for product, increased manufacturing costs, decreases in product market price, economic, regulatory, practical or other impediments to anticipated market expansion, and insufficient product demand. More information on these risks and other potential factors that could affect our business, reputation, results of operations, financial condition, and stock price is included in our filings with the SEC and subsequent filings. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Related Quotes
In this article, we will take a look at the 11 best buy-the-dip stocks to buy now. If you want to see more stocks in this selection, go to the 5 Best Buy-the-Dip Stocks To Buy Now. The leading US market indices are on their way to recording the first annual loss since 2018 and the […]
Yahoo Finance’s Pras Subramanian joins the Live show to discuss reports that Elon Musk has addressed Tesla staff in a memo thanking them for a strong fourth quarter and assuring them to not be bothered by stock price uncertainty.
And what it means for your ability to build wealth.
Based on the agreement Elon Musk signed to help fund his Twitter purchase, he has experienced his first margin call because of Tesla's stock-price declines.
No matter how volatile the stock market is in 2023, these tried-and-true companies can deliver for their shareholders.
The Federal Reserve gave the stock market a shock recently as the central bank raised interest rates once again, taking its benchmark rate to its highest level in 15 years. The Fed also suggested that it would keep raising rates in 2023 to bring down inflation. The Fed's hawkish stance sent equities tumbling, as it was expected that the central bank would dial down rate increases in 2023 thanks to signs of cooling inflation.
Yahoo Finance Live anchors discuss the decline in stock for Cal-Maine Foods despite topping revenue expectations.
Any time an industry is in turmoil, a company within it can see notable volatility in its stock price, with some movements making less sense than others. On Wednesday, one of the more up-and-down titles in the sector, Carvana (NYSE: CVNA), saw a counterintuitive rise. The company's share price ended the day 3% higher, despite yet another negative analyst note on its prospects.
In this article, we discuss the 12 cheap value stocks to buy according to Warren Buffett. If you want to skip our discussion, go directly to 5 Cheap Value Stocks to Buy According to Warren Buffett. Warren Buffett and His Investment Strategy Warren Buffett is one of the most successful investors in the world and […]
U.S. stock index futures bounce back on Thursday after the Nasdaq nearly hit a 30-month low a day earlier as the market looked set to erase some of its recent losses on the second-to-last trading day of the year.
All three of these high-yield dividend stocks have a long history of annual payout raises and an ability to raise their distributions without breaking their balance sheets. Shares of AbbVie (NYSE: ABBV) have risen more than 50% from a low point in October. Right now, AbbVie's dividend doesn't offer much more than a savings account.
In this article, we will take a look at the 12 best 52-week high stocks to buy now. If you want to see more stocks in this selection, go to the 5 Best 52-Week High Stocks To Buy Now. The equity markets have been taking a beating this year as the Dow Jones Industrial Average […]
The last 12 months have seen a combination of volatile trading and a relentlessly downward trend in the stock market. The end result, in this last week of the year, is broad based losses – a 21% ytd drop in the S&P 500, and 35% in the NASDAQ – that have hurt investors and cut into portfolio returns. But even in a bearish year, investors can still find islands of opportunity. The key here is to recognize those stocks that are oversold, that have seen worse losses than they should have. These are
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in RAYALDEE.
A maker of medical equipment that in October said it had 146 full-time workers now says it will close its St. Louis plant and lay off 160 employees, citing "ongoing losses from operations."
Both businesses are well-suited for producing passive income, but only one has the balance sheet and future prospects to make it work.
The Oracle of Omaha's preferred length of time to hold an investment is "forever" — which is quite a long holding period. It's perfectly fine to consider following Buffett into a couple of his stock positions as long as you're willing to be as patient as he is and refrain from selling for quite some time. Johnson & Johnson (NYSE: JNJ) only accounts for around 0.02% of Buffett's portfolio, but it's a strong example of how and why his investing strategy is successful over time.
Upbeat air-travel demand bodes well for American Airlines (AAL).
The average brokerage recommendation (ABR) for NIO Inc. (NIO) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
My children have inherited $5 million of stock from their father (whose estate has not yet been dispersed after 11 months) leaving them with a 30% or so loss of value over which they have had no control. Is there … Continue reading → The post Ask an Advisor: My Kids Inherited $5 Million. How Should They Handle It? appeared first on SmartAsset Blog.